Physician profile
Nathan J Maltezos
NPI 1427477462
$9,979.58
in general payments reported to CMS, 2019-2025
33 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,398 · 2020: $267 · 2021: $1,316 · 2022: $1,379 · 2023: $1,045 · 2024: $2,108 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,331 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,330.55 |
| Travel and Lodging | $289.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,420.75 | 2019-2025 | Eterna, Octrode, Proclaim |
| Medtronic, INC. | $633.49 | 2024-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Nevro Corp. | $598.97 | 2019-2024 | Senza |
| Vertos Medical, INC. | $552.04 | 2021-2024 | Mild Device Kit |
| Boston Scientific Corporation | $419.72 | 2019-2024 | Intracept, Wavewriter Alpha Prime 16 |
| Curonix LLC | $304.58 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Globus Medical, INC. | $288.32 | 2025 | Senza |
| Vertiflex, INC. | $278.13 | 2019 | |
| Abbvie INC. | $175.24 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $152.98 | 2023-2025 | Horizant, Horizant |
| Relievant Medsystems, INC. | $142.27 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $109.03 | 2024-2025 | |
| Foundation Fusion Solutions, LLC | $104.90 | 2022-2025 | |
| Si-Bone, INC. | $98.82 | 2025 | |
| Averitas Pharma INC. | $85.76 | 2024-2025 | Qutenza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $79.37 | 2024-2025 | Evoke |
| Medtronic USA, INC. | $55.07 | 2019 | |
| Ossur Americas, INC. | $53.24 | 2025 | Unloader One X |
| Spr Therapeutics, INC | $49.74 | 2019-2025 | Sprint Pns System |
| Nalu Medical, INC. | $49.15 | 2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.89 | 2025 | Relistor |
| Zimmer Biomet Holdings, INC. | $44.16 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Appliedvr INC | $41.68 | 2025 | Relievrx |
| Trice Medical, INC. | $31.12 | 2025 | |
| Spinal Simplicity, LLC | $24.81 | 2025 | Ha Minuteman G3-R |
| Fidia Pharma USA INC. | $21.63 | 2025 | Triluron |
| Takeda Pharmaceuticals U.S.A., INC. | $20.00 | 2024 | Eohilia |
| Painteq LLC | $18.90 | 2024 | Painteq |
| Djo, LLC | $18.65 | 2025 | Donjoy |
| Collegium Pharmaceutical, INC. | $16.71 | 2023 | Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Avanos Medical | $14.74 | 2019 | |
| Grt US Holding, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Maltezos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.